Magnesium%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520sulphate

# Magnesium Sulphate ## Overview Magnesium sulfate is an essential mineral and electrolyte that plays a critical role in numerous physiological processes, including neuromuscular function, cardiac contractility, and enzyme activity. It is available in intravenous (IV) and intramuscular (IM) formulations. ## Primary Indications * **Eclampsia and Preeclampsia:** Prevention and treatment of seizures in pregnant women with severe preeclampsia or eclampsia. * **Torsades de Pointes:** Treatment of polymorphic ventricular tachycardia (torsades de pointes) associated with a prolonged QT interval. * **Hypomagnesemia:** Treatment of magnesium deficiency. * **Bronchospasm:** Adjunctive therapy for severe acute asthma or COPD exacerbations, particularly when unresponsive to standard bronchodilators. * **Constipation:** Oral magnesium sulfate can be used as a saline laxative. ## Adult Dosing * **Eclampsia/Preeclampsia (Loading Dose):** 4-6 grams IV infused over 5-20 minutes. * **Eclampsia/Preeclampsia (Maintenance Dose):** 1-2 grams/hour IV infusion. Some protocols may use intermittent IM doses (e.g., 5 grams IM every 4 hours). **Dosing is often guided by local institutional protocol.** * **Torsades de Pointes:** 1-2 grams IV diluted in 10-20 mL D5W, infused over 5-10 minutes. May repeat every 5-15 minutes as needed. Subsequent infusion of 0.5-1 gram/hour may be used. * **Hypomagnesemia:** * **Severe deficiency (serum Mg < 1.5 mEq/L):** 4-5 grams (approximately 32-40 mEq) IV in 1 L normal saline or D5W over 4 hours, or administer as 5 grams IM (2.5 grams in each buttock) in 1% procaine solution. * **Less severe deficiency:** 2-3 grams (16-24 mEq) IV in 1 L normal saline or D5W over 4 hours. * **Maintenance:** 1 gram (8 mEq) IV infusion over 24 hours. * **Bronchospasm (Adjunctive):** 1-2 grams IV diluted in 100 mL normal saline, infused over 15-20 minutes. * **Constipation (Oral):** 15-30 grams dissolved in water, taken once. ## Pediatric Dosing * **Eclampsia/Preeclampsia:** Data in pediatric populations is limited. Dosing typically follows adult guidelines, adjusted for weight and renal function, and often guided by specialist consultation. * **Hypomagnesemia:** Dosing is highly variable and dependent on age, weight, and severity of deficiency. * **Loading Dose:** 25-50 mg/kg/dose (0.1-0.2 mEq/kg/dose) IV over 10-20 minutes. Maximum loading dose typically 2 grams. * **Maintenance Dose:** 0.1-0.2 mEq/kg/hour (up to 10 mEq/hour). **Dosing requires careful calculation and monitoring by a pediatric specialist.** * **Torsades de Pointes:** 25-50 mg/kg IV as a single dose, maximum 2 grams. May repeat every 5-15 minutes. Subsequent infusion of 10-20 mg/kg/hour. * **Bronchospasm (Adjunctive):** 25-50 mg/kg IV (maximum 2 grams) infused over 15-20 minutes. ## Dose Adjustments * **Renal Impairment:** Magnesium is renally excreted. Reduce dose and monitor serum magnesium levels closely in patients with impaired renal function. If CrCl < 30 mL/min, doses should be reduced by 50%. In severe renal failure, magnesium sulfate may be contraindicated. * **Hepatic Impairment:** No specific dose adjustment needed, but monitor magnesium levels as hepatic dysfunction can sometimes affect electrolyte balance. ## Contraindications * Hypermagnesemia. * Heart block. * Myocardial infarction (in patients with heart block). * Anuria. * Hypersensitivity to magnesium sulfate. ## Adverse Effects * **Common:** Flushing, sweating, hypotension, nausea, vomiting, decreased deep tendon reflexes, drowsiness. * **Serious:** Respiratory depression, cardiac arrest, hypermagnesemia (symptoms include absent reflexes, hypotension, ECG changes, somnolence, confusion, respiratory paralysis, cardiac arrest). ## Key Drug Interactions * **Neuromuscular Blocking Agents (e.g., succinylcholine, vecuronium):** Magnesium sulfate can potentiate neuromuscular blockade, leading to profound muscle weakness and respiratory depression. Use with caution and monitor closely. * **Calcium Channel Blockers:** Additive hypotensive effects. * **Antibiotics (e.g., tetracyclines, fluoroquinolones):** Magnesium can decrease the absorption of oral forms of these antibiotics. Administer magnesium at least 2 hours before or 4-6 hours after these antibiotics. * **Digoxin:** High doses of IV magnesium sulfate may cause cardiac arrhythmias in patients taking digoxin. ## Monitoring * **Serum Magnesium Levels:** Crucial for guiding therapy and preventing toxicity, especially with IV or IM administration. Target levels vary by indication. * **Renal Function:** Monitor serum creatinine and BUN. * **Vital Signs:** Blood pressure, heart rate, respiratory rate. * **Neurological Status:** Deep tendon reflexes, level of consciousness. * **Urine Output:** Monitor for adequate renal function. * **ECG:** For patients receiving IV magnesium, especially for torsades de pointes or those with cardiac history. ## Clinical Pearls * IV magnesium sulfate should always be diluted and infused slowly to prevent hypotension and respiratory depression. * Always have calcium gluconate readily available as an antidote for magnesium toxicity. * In eclampsia, it is crucial to monitor respiratory rate; if it falls below 12 breaths/minute, stop the infusion and administer calcium gluconate. * Oral magnesium sulfate is generally well-tolerated but can cause diarrhea. * Electrolyte imbalances, particularly calcium and potassium, should be assessed and corrected concurrently when treating hypomagnesemia. --- *This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols for definitive guidance.*